Risk Review
Dr. Farag reviews your personal and family cancer history, current screenings, and overall risk factors.
Guardant Health Shield Test in Fort Myers, FL
Multi-Cancer Blood Test
Your Guardant Health Shield Test at a glance:
Treatment Time:10-15 minutes
Sample Type:Blood draw
Results:2-4 weeks
Downtime:None
The Gap in Standard Cancer Screening
Why Most Cancers Go Undetected Early
Standard cancer screening protocols only cover a handful of cancer types: breast, cervical, colorectal, lung in select smokers, and prostate. The vast majority of cancer types have no routine screening test at all, which means many cancers are not identified until they cause symptoms or appear on imaging for unrelated reasons. By that stage, the disease is often more advanced and harder to treat. Even patients who diligently complete every recommended screening still face significant blind spots in their preventive care.
The Shield multi-cancer detection test at RegalMed Clinic adds a complementary layer to your screening strategy. Using a single blood draw, the test analyzes circulating cell-free DNA for methylation changes and fragmentomic patterns associated with multiple cancer types. Dr. Farag integrates Shield results with your full health history, family risk factors, and standard screenings such as colonoscopy and mammogram, creating a more comprehensive early-detection plan tailored to your individual longevity goals.
What Is the Shield Multi-Cancer Detection Test?
Blood-Based cfDNA Cancer Screening
The Shield Multi-Cancer Detection (MCD) test is a blood-based screening test developed by Guardant Health. It is designed to detect cancer signals in the bloodstream by analyzing fragments of cell-free DNA (cfDNA) shed by cells throughout the body, including potential tumor cells.
How the Shield Test Works
When cells turn over, they release small DNA fragments into the bloodstream. The Shield test isolates this circulating cell-free DNA and examines three layers of biological information: genomic alterations, methylation patterns (chemical tags on DNA that change in cancer), and fragmentomic signatures (the size and distribution of DNA fragments). Machine learning models trained on cancer and non-cancer samples interpret these features to identify whether a cancer signal is present, and in some cases, suggest where in the body it may be coming from. According to the National Cancer Institute, multi-cancer detection blood tests represent an emerging area of cancer screening research.
What the Shield Test Screens For
Shield is intended to screen for cancer signals across multiple cancer types from a single blood draw. It is positioned as a complement to, not a replacement for, standard age-appropriate screening such as colonoscopy, mammogram, low-dose CT for eligible smokers, and Pap testing. Patients still need to complete those recommended tests on schedule.
Shield Results and Next Steps
A negative result suggests no cancer signal was detected at the time of testing and does not eliminate the need for ongoing screening. A positive result indicates a cancer signal was detected and prompts a structured diagnostic workup. Dr. Farag interprets every result in the context of your full clinical picture and coordinates any necessary follow-up imaging or specialist referral.
Treatment Timeline
Blood Draw
Single venipuncture, 10-15 minutes
Lab Processing
cfDNA isolation and analysis, 2-4 weeks
Results Review
Detailed consultation with Dr. Farag
Retest Interval
Annually as part of preventive care
Benefits of the Shield Test
Multi-Cancer Detection from One Blood Draw
- 01
Single Blood Draw
One simple venipuncture screens for cancer signals across multiple types
- 02
Complement to Standard Screening
Adds early-detection coverage beyond mammogram, colonoscopy, and lung CT
- 03
Non-Invasive
No imaging contrast, scopes, or radiation, just a routine blood sample
- 04
Earlier Signal Detection
Designed to identify cancer signals before symptoms typically appear
- 05
Multi-Layered Analysis
Examines methylation, fragmentomics, and genomic features in one assay
- 06
Personalized Follow-Up
Dr. Farag reviews every result and coordinates any next steps
Shield Test vs Alternatives
Compare Your Options
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| Shield Test | cfDNA methylation and fragmentomic analysis | 10-15 min draw | 2-4 weeks | Annual screening | None | Adding multi-cancer signal detection to standard screening |
| Galleri Test | cfDNA methylation analysis for 50+ cancer types | 10-15 min draw | 2-4 weeks | Annual screening | None | Broad multi-cancer methylation screening with tissue of origin |
| Standard Cancer Screening | Mammogram, colonoscopy, low-dose CT, Pap, PSA | Varies by test | Days to weeks | Per guideline schedule | Minimal to moderate | Guideline-directed screening for specific cancer types |
Who Should Consider the Shield Test?
Candidacy Assessment
The Shield multi-cancer detection test is most appropriate for adults who are committed to ongoing standard age-appropriate screening and want an additional layer of early detection. Dr. Farag reviews your personal and family cancer history during consultation to determine whether Shield aligns with your preventive care plan.
Ideal Candidates for the Shield Test
- Adults age 45 and older who are at average to elevated risk for cancer
- Patients with a strong family history of multiple cancer types
- Individuals who are current with mammogram, colonoscopy, lung CT, and other recommended screenings
- Patients focused on longevity and proactive preventive care
- Adults who want a non-invasive, blood-based complement to imaging and endoscopic screening
Who Should Wait or Speak with Dr. Farag First
- Patients with a current active cancer diagnosis or recent treatment, since the test is for screening, not monitoring
- Individuals with current symptoms suggesting cancer, who need diagnostic workup rather than screening
- Patients pregnant or recently pregnant, since this can affect cfDNA analysis
- Adults who are not up to date on standard screening, who should complete those tests first
According to the National Cancer Institute, no screening test is perfect. Shield is designed as a complement to standard screening, not a replacement, and Dr. Farag will help you decide whether it fits your individual risk profile.
What Happens During Your Shield Test
Eligibility Check
Dr. Farag confirms you are age-eligible, currently asymptomatic, and up to date on standard screening.
Blood Draw
A trained phlebotomist collects blood samples through a single venipuncture, typically 10-15 minutes.
Lab Analysis
The Guardant Health lab isolates cfDNA and analyzes methylation and fragmentomic patterns over 2-4 weeks.
Results Consultation
Dr. Farag reviews your result, explains its meaning, and coordinates any diagnostic follow-up if needed.
Side Effects & Considerations
What to Know
The Shield test itself is a standard blood draw with minimal physical risk. The most important considerations relate to how the result is interpreted, not to the procedure.
Common Side Effects
- Minor bruising or tenderness at the venipuncture site, usually resolving within 1-2 days
- Brief lightheadedness during or immediately after the draw, which is uncommon
Important Considerations
- A negative result does not mean cancer is absent, it means no cancer signal was detected at the time of testing
- A positive result is not a cancer diagnosis, it indicates a cancer signal was detected and requires diagnostic follow-up such as imaging or biopsy
- Shield does not replace standard age-appropriate screening such as colonoscopy, mammogram, low-dose CT, and Pap testing
- Recent pregnancy, certain non-malignant conditions, and prior cancer treatment may influence cfDNA results
- No screening test, including Shield, detects every cancer at every stage
Safety and Regulatory Status
The blood draw carries no systemic risk when performed under standard clinical conditions. Multi-cancer detection blood tests are an emerging category, and Dr. Farag will discuss the current evidence and the test's intended use with you so that your decision to add Shield to your screening plan is fully informed.
Shield Test Cost in Fort Myers
Transparent Cancer Screening Pricing
The Shield multi-cancer detection test at RegalMed Clinic is a strategic addition to your preventive care, designed to complement the standard cancer screenings you already complete with Dr. Farag.
Pricing Overview
The Shield test is typically priced in the $700-$950 range when paid out of pocket, depending on Guardant Health's current cash-pay program. This includes the blood draw, laboratory analysis, and a thorough results review with Dr. Farag.
What's Included
- Initial consultation, family history review, and risk assessment
- Blood draw and specimen processing
- Guardant Health Shield cfDNA analysis
- Follow-up consultation with detailed results interpretation
- Coordination of any diagnostic follow-up if a cancer signal is detected
Insurance & Payment
Coverage for multi-cancer detection blood tests varies by insurance plan and is evolving as the science matures. Some plans cover Shield in specific clinical scenarios, while many patients pay out of pocket through Guardant Health's cash-pay program. RegalMed Clinic accepts major credit cards and can provide documentation for HSA/FSA reimbursement. Contact our Fort Myers office at (239) 395-2434 for current pricing details.
Why Choose RegalMed Clinic
Fort Myers Preventive Medicine
Physician Interpretation
Dr. Farag personally reviews every Shield result in the context of your full health profile
Two MCD Options
Regal Med offers both Shield and Galleri so we can match the right test to you
Coordinated Follow-Up
Positive results trigger a structured diagnostic workup, not a phone call and silence
Preventive Medicine Focus
Cancer screening is integrated with longevity, metabolic, and functional medicine care
Related Services
Cancer Screening
Advanced Diagnostic Testing
Shield Test FAQ
Answers to Your Questions
01 What is the Shield Multi-Cancer Detection test?
Shield is a blood-based screening test from Guardant Health that analyzes cell-free DNA, methylation patterns, and fragmentomic signatures to detect cancer signals across multiple cancer types from a single blood draw. It is designed to complement standard age-appropriate screening, not replace it.
02 Does Shield diagnose cancer?
No. Shield is a screening test, not a diagnostic test. A positive result indicates a cancer signal was detected and prompts a structured diagnostic workup, typically imaging or biopsy. Dr. Farag coordinates any follow-up testing if a signal is found.
03 Do I still need a colonoscopy and mammogram if I get the Shield test?
Yes. Shield does not replace colonoscopy, mammogram, low-dose CT for eligible smokers, Pap testing, or other guideline-recommended screenings. It is intended as an additional layer that complements those tests.
04 How is Shield different from the Galleri test?
Both Shield and Galleri use cell-free DNA and methylation analysis to screen for cancer signals from a blood draw, but they use different proprietary assays and machine learning models. Regal Med Clinic offers both, and Dr. Farag helps match the right test to your situation.
05 Do I need to fast before the Shield test?
Most patients do not need to fast for the Shield test, but Dr. Farag will provide specific preparation instructions when you schedule your appointment to ensure the most accurate result.
06 How often should I repeat the Shield test?
Shield is generally repeated annually as part of ongoing preventive care, alongside your standard age-appropriate screenings. Dr. Farag tailors the interval to your personal and family cancer risk profile.
07 What happens if my Shield test is positive?
A positive result triggers a structured diagnostic workup, which may include imaging, additional lab work, or specialist referral. Dr. Farag personally coordinates these next steps and walks you through the plan during your results consultation.
08 Can the Shield test miss a cancer?
Yes. No screening test detects every cancer at every stage. A negative Shield result does not rule out cancer, which is why ongoing standard screening and attention to new symptoms remain essential parts of preventive care.
Location15750 New Hampshire Ct, STE D
Fort Myers, FL, 33908
Fort Myers, FL, 33908
Phone(239) 395-2434
Schedule Your Guardant Health - Shield Multi-Cancer Detection Test Consultation
References
- PubMed (PMID: 38598794) - Sensitivity and specificity of a cell-free DNA blood-based test for colorectal cancer screening (Shield ECLIPSE study, NEJM 2024).
- PubMed (PMID: 32428494) - Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
- PubMed (PMID: 34176935) - Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (CCGA substudy 3).
- PubMed (PMID: 36057017) - The PATHFINDER study: assessment of the implementation of a multi-cancer early detection test in a clinical setting.
- PubMed (PMID: 28814544) - Fragment length of circulating tumor DNA reveals fragmentomic features that distinguish cancer from non-cancer samples.
- PubMed (PMID: 35804282) - Genome-wide cell-free DNA fragmentation in patients with cancer (DELFI approach to fragmentomic cancer detection).